Commentary
Volume 08:03, 2024

Reports in Thyroid Research

ISSN: 2684-4273 Open Access

Exploring Diurnal Expression Patterns of Tsh-R and Circadian Clock Genes in Thyrocytes as Potential Preoperative Biomarkers for Thyroid Carcinoma

Dougados Diallo*

Department of Endocrinology, University of the French Antilles, Pointe-à-Pitre, France

Introduction

The exploration of diurnal expression patterns of Thyroid-Stimulating Hormone Receptor and circadian clock genes in Thyrocytes presents a promising avenue for identifying preoperative biomarkers for thyroid carcinoma. Thyroid cancer remains one of the most common endocrine malignancies, and its incidence has been rising steadily over the past few decades. While advancements in diagnostic technologies have improved detection rates, identifying reliable biomarkers for early diagnosis and prognosis remains a critical challenge. Biomarkers derived from gene expression patterns have shown potential in recent years, particularly when linked to the body's inherent biological rhythms. The circadian system, which governs nearly all physiological and cellular processes in a time-dependent manner, may hold the key to uncovering new, clinically relevant biomarkers for thyroid carcinoma. TSH-R is a well-known receptor that plays a pivotal role in thyroid physiology, including hormone synthesis, cell growth, and differentiation. Its dysregulation has been associated with various thyroid pathologies, including thyroid carcinoma. Recent studies have highlighted the temporal variability in TSH-R expression, suggesting that its activity may be influenced by circadian rhythms. The circadian clock, regulated by a set of core clock genes such as CLOCK, BMAL1, PER, and CRY, orchestrates rhythmic gene expression in virtually every cell, including Thyrocytes. Aberrations in circadian rhythms and clock gene expression have been implicated in the development and progression of various cancers, including thyroid carcinoma. Therefore, investigating the interplay between TSH-R expression and circadian clock gene dynamics offers a unique perspective on tumor biology and its potential clinical applications [1].

Description

Diurnal variations in TSH-R expression could provide insight into the underlying mechanisms of thyroid carcinoma. Thyrocytes, the primary cells of the thyroid gland, are highly responsive to TSH, which exhibits circadian oscillations in secretion. This rhythmic secretion of TSH suggests that TSH-R expression in Thyrocytes may also follow a diurnal pattern. Understanding how these patterns differ between normal and cancerous thyroid tissues could reveal novel biomarkers that reflect tumor-specific disruptions in circadian regulation. For example, altered amplitude, phase, or periodicity of TSH-R expression in carcinoma tissues could serve as a distinguishing feature, aiding in the early detection of malignancy.

***Address for Correspondence:** Dougados Diallo, Department of Endocrinology, University of the French Antilles, Pointe-à-Pitre, France; E-mail: dougadosiallo@hns.com*

Received: 02 September, 2024, Manuscript No. rtr-24-155441; **Editor Assigned:** 04 September, 2024, PreQC No. P-155441; **Reviewed:** 18 September, 2024, QC No. Q-155441; **Revised:** 23 September, 2024, Manuscript No. R-155441; **Published:** 30 September, 2024, DOI: 10.37421/2684-4273.2024.8.82

Moreover, circadian clock genes themselves are increasingly recognized as critical players in tumorigenesis. These genes regulate a wide range of cellular processes, including cell cycle progression, DNA repair, apoptosis, and metabolism. Dysregulation of circadian clock genes has been associated with increased cancer risk, including in the thyroid gland. For instance, studies have demonstrated altered expression of core clock genes such as PER1, PER2, and CRY2 in thyroid carcinoma tissues compared to normal thyroid tissues. Such findings suggest that disruptions in the circadian clock may contribute to the pathogenesis of thyroid carcinoma and that these disruptions could be exploited as biomarkers [2].

One of the key advantages of using diurnal expression patterns as biomarkers is their potential to capture dynamic changes in tumor biology. Static biomarkers, such as single-time-point measurements of protein or gene expression, may miss important temporal variations that reflect disease state. By contrast, assessing diurnal profiles allows for a more comprehensive understanding of biological rhythms and their alterations in cancer. This approach could enable the identification of biomarkers that are not only sensitive to the presence of disease but also specific to its stage and subtype. For instance, certain thyroid carcinoma subtypes may exhibit unique diurnal expression patterns of TSH-R and clock genes, which could aid in subtype classification and personalized treatment planning. To translate these findings into clinical practice, it is essential to address several methodological and logistical challenges. First, the collection of thyroid tissue samples at multiple time points over a 24-hour period is required to generate diurnal profiles. This may be logistically challenging in clinical settings, especially for preoperative patients. Non-invasive or minimally invasive sampling methods, such as fine-needle aspiration biopsies, could help overcome this limitation. Additionally, high-throughput techniques such as quantitative PCR, RNA sequencing, and proteomics will be critical for accurately quantifying gene and protein expression levels at different time points. Standardizing these techniques and ensuring their reproducibility across different laboratories will be essential for validating diurnal biomarkers [3]. Another challenge is the potential influence of external factors on diurnal gene expression. Environmental cues such as light exposure sleep patterns, and dietary habits can affect circadian rhythms, introducing variability into gene expression profiles. Therefore, careful control of these factors during sample collection and analysis is necessary to ensure the reliability of results. Longitudinal studies that monitor the same individuals over time may also help account for inter-individual variability and strengthen the validity of diurnal biomarkers [4].

In addition to these technical considerations, it is important to address the broader implications of using diurnal biomarkers for preoperative diagnosis. For instance, integrating diurnal biomarkers into existing diagnostic workflows may require new protocols for sample collection, processing, and interpretation. This could increase the complexity and cost of diagnosis, at least initially. However, the long-term benefits of early and accurate detection could outweigh these challenges, particularly if diurnal biomarkers improve diagnostic specificity and reduce unnecessary surgical interventions. Furthermore, diurnal biomarkers could complement existing diagnostic tools, such as ultrasound and fine-needle aspiration cytology, by providing additional molecular-level information. The identification of diurnal biomarkers also has implications for therapeutic strategies. For example, understanding the temporal dynamics of TSH-R and clock gene expression

could inform the timing of therapeutic interventions, a concept known as chronotherapy. By aligning treatment schedules with the patient's circadian rhythms, it may be possible to enhance therapeutic efficacy and minimize side effects. This approach could be particularly relevant for thyroid carcinoma, given the circadian regulation of thyroid hormone metabolism and the role of TSH in tumor progression [5].

Conclusion

Testing diurnal profiles of TSH-R and circadian clock gene expression in Thyrocytes represents a promising approach for identifying preoperative biomarkers for thyroid carcinoma. This innovative strategy leverages the intrinsic biological rhythms of the thyroid gland to uncover dynamic molecular signatures of disease. While there are significant challenges to overcome, including logistical, technical, and interpretative issues, the potential benefits of diurnal biomarkers are substantial. They could improve the accuracy of early diagnosis, enable better risk stratification, and open new avenues for personalized treatment. As research in this field continues to evolve, it holds the promise of transforming our understanding and management of thyroid carcinoma, ultimately improving outcomes for patients.

Acknowledgement

None.

Conflict of Interest

None.

References

1. Philippe Jacques and Charna Dibner. "Thyroid circadian timing: Roles in physiology and thyroid malignancies." *J Biol Rhythms* 30 (2015): 76-83.
2. Cibas Edmund S. and Syed Z Ali. "The Bethesda system for reporting thyroid cytopathology." *Thyroid* 19 (2009): 1159-1165.
3. Dibner Charna, Samira Mercedes Sadowski, Frederic Triponez and Jacques Philippe. "The search for preoperative biomarkers for thyroid carcinoma: Application of the thyroid circadian clock properties." *Biomark med* 11 (2017): 285-293.
4. Malaguarnera Roberta, Caterina Ledda, Agnese Filippello and Francesco Frasca, et al. "Thyroid cancer and circadian clock disruption." *Cancers* 12 (2020): 3109.
5. Gao Zhifei Xueibai, Guoting Chen, Jie Liu and Weizhi Ouyang, et al. "Diurnal oscillations of epigenetic modifications are associated with variation in rhythmic expression of homoeologous genes in Brassica napus." *BMC Biology* 21 (2023): 1.

How to cite this article: Diallo, Dougados. "Exploring Diurnal Expression Patterns of Tsh-R and Circadian Clock Genes in Thyrocytes as Potential Preoperative Biomarkers for Thyroid Carcinoma." *Rep Thyroid Res* 8 (2024): 82.